Mingqian Wei

Title: Innovations of Mingqian Wei in Cancer Treatment

Introduction

Mingqian Wei is a notable inventor based in Jinan, China. He has made significant contributions to the field of medicine, particularly in the treatment of non-small cell lung carcinoma. His innovative approach combines biological derivatives with established cancer treatments to enhance therapeutic efficacy.

Latest Patents

Mingqian Wei holds a patent for the "Application of Derivatives of Clostridium Ghonii," specifically focusing on the derivatives of MW-DCG-HNCv-18. This invention details the preparation of medicines aimed at treating non-small cell lung carcinoma. The patent reveals that the MW-DCG-HNCv-18 strain exhibits a specific inhibitory effect on non-small cell lung carcinoma, which is significantly superior to that of other known similar strains. Furthermore, the combination of the MW-DCG-HNCv-18 strain with Docetaxel as active ingredients has been shown to produce a more pronounced inhibition effect on the cancer.

Career Highlights

Mingqian Wei has worked with Shandong Xinchuang Biotechnology Co., Ltd. and Shandong Xinchuang Biological Technology Co., Ltd. These experiences have allowed him to develop and refine his innovative ideas in biotechnology and cancer treatment.

Collaborations

Mingqian Wei has collaborated with notable colleagues such as Laitian Xing and Yong Wang. Their joint efforts have contributed to the advancement of research in the field of cancer therapies.

Conclusion

Mingqian Wei's work exemplifies the intersection of innovation and medicine, particularly in the fight against non-small cell lung carcinoma. His patented inventions and collaborations highlight the potential for new treatments that can significantly improve patient outcomes.